Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

Inclusion Criteria: * Patients must have pathologically-confirmed, previously untreated, clinically accessible (without general anesthesia) locally advanced squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or nonresectable head and neck squamous cell carcinomas of the skin. * Patients will be limited to: * ≥ 70 years of age, OR * with co-morbidities that preclude treatment with standard platinum-based chemotherapy, as determined by the treating physician, OR * KPS ≤ 80, OR * Creatinine clearance \< 30 cc/min * Laboratory criteria: * WBC \> 3500/ul * Granulocyte \> 1500/ul * Platelet count \> 100,000/ul * Total Bilirubin \< 1.5 X ULN * AST and ALT \< 2.5 X ULN * Patients must give documented informed consent to participate in this study. Exclusion Criteria: * Prior head and neck malignancy, or history of other prior non-head and neck malignancy within the past 3 years (excluding skin cancer and early stage treated prostate cancer). * Prior head and neck radiation or chemotherapy. * Documented evidence of distant metastases. * Patients with nasopharyngeal carcinoma. * Any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment. * Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible. * Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule). * Patients residing in prison.